Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer Academic Article uri icon

Overview

MeSH Major

  • Absorptiometry, Photon
  • Aromatase Inhibitors
  • Bone Density Conservation Agents
  • Breast Neoplasms
  • Diphosphonates
  • Drug Costs
  • Fractures, Bone

abstract

  • In postmenopausal women receiving adjuvant AIs for HR-positive EBC, a policy of baseline and annual BMD screening followed by selective treatment with oral bisphosphonates for those diagnosed with osteoporosis is a cost-effective use of societal resources.

publication date

  • May 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2011.38.7001

PubMed ID

  • 22370313

Additional Document Info

start page

  • 1468

end page

  • 75

volume

  • 30

number

  • 13